David Proudman


Menlo Park


M.P.H., health policy and management, University of California, Berkeley; M.Biochem., molecular and cellular biochemistry, Oxford University

Summary of Experience

Mr. Proudman is a health economist with over a decade of experience in the US and global biopharmaceutical industry, specializing in economic modeling and market access strategy. His health economic modeling projects at Analysis Group have included cost-effectiveness and budget impact models, indirect treatment comparisons and evidence generation strategy, reimbursement submissions, and preparation for early scientific advice. In the area of market access, Mr. Proudman has performed primary and secondary research to synthesize and validate value messaging and pricing. He has worked in a number of disease areas, particularly oncology, central nervous system, cardiovascular, immunology, and ophthalmology. Prior to joining Analysis Group, Mr. Proudman was director of research and head of health care and technology at a global growth investment fund. He has also worked as a data scientist at the UCSF Center for Healthcare Value; as a lecturer in health economics and finance at the University of California, Berkeley; and as a project manager on observational data projects at NICE’s Centre for Health Technology Evaluation in the UK.

Selected Publishing